Compare MD & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MD | APLT |
|---|---|---|
| Founded | 1979 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 18.0M |
| IPO Year | 1995 | 2019 |
| Metric | MD | APLT |
|---|---|---|
| Price | $22.00 | $0.13 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 4 | 3 |
| Target Price | ★ $21.00 | $1.25 |
| AVG Volume (30 Days) | 1.2M | ★ 8.6M |
| Earning Date | 11-03-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.91 | N/A |
| Revenue | ★ $1,922,442,000.00 | $1,000,000.00 |
| Revenue This Year | N/A | $124.18 |
| Revenue Next Year | $2.70 | $66.67 |
| P/E Ratio | $11.48 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.84 | $0.10 |
| 52 Week High | $24.99 | $1.50 |
| Indicator | MD | APLT |
|---|---|---|
| Relative Strength Index (RSI) | 49.64 | 26.92 |
| Support Level | $21.41 | $0.10 |
| Resistance Level | $22.68 | $0.13 |
| Average True Range (ATR) | 0.74 | 0.02 |
| MACD | -0.22 | 0.02 |
| Stochastic Oscillator | 30.93 | 15.95 |
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.